Statistical analyses
efficacy/death
REGRESSION
The ARR for the newly switched and continuous ofatumumab groups was estimated using a piecewise negative binomial model. Cumulative 3/6mCDW were assessed using Kaplan–Meier curves. Lesions per scan and adjusted annualized rates of lesions were estimated using piecewise negative binomial models. Between-group comparisons for number of relapses and number of lesions were analyzed using the Wilcoxon rank sum test. sNfL concentration was analyzed by mixed-effect modeling of repeated measures. NEDA-3 during the core and extension periods, and overall was analyzed separately using logistic regression models fitted to modified efficacy analysis sets, which excluded patients who discontinued early for reasons other than lack of efficacy/death and had NEDA-3 prior to discontinuation.